For decades, researchers have understood that cancer is primarily a disease of genetic mutation. However, the role of the immune system and the body's inflammatory response has emerged as a critical piece of the puzzle. When inflammation becomes chronic, it shifts from being a defense mechanism to an enabler of tumor growth.

The tumor microenvironment (TME) is a complex ecosystem. It consists not only of cancer cells but also of immune cells, blood vessels, and signaling molecules. Among these, inflammatory cytokines play a paradoxical role. "We used to think the immune system always fought cancer," says Dr. Hassan, lead researcher at CRI. "Now we know that certain immune cells, when chronically activated, actually build the scaffolding that tumors use to grow."

The Cellular Mechanisms

Macrophages are a prime example. While their primary job is to engulf and digest cellular debris and pathogens, tumors can biochemically reprogram them. These Tumor-Associated Macrophages (TAMs) secrete growth factors that promote angiogenesis—the formation of new blood vessels that feed the tumor.

"Inflammation is the fire that fuels the engine of cancer progression. If we can extinguish the fire, we can starve the engine."

Recent studies in our own laboratories have focused on the NF-κB signaling pathway. This pathway acts as a master switch for inflammation. When abnormally active, it prevents cancer cells from undergoing apoptosis (programmed cell death) while simultaneously encouraging them to proliferate.

Implications for Treatment

Understanding this relationship opens new avenues for therapy. By combining traditional chemotherapy with anti-inflammatory agents, we may be able to dismantle the supportive microenvironment. Clinical trials at affiliated hospitals are already investigating whether targeting specific cytokines, like IL-6, can improve outcomes for patients with treatment-resistant breast cancer.